Virus Watch, supported by NHS Test and Trace, provides information regarding patients’ antibodies and this includes immunocompromised patients, such as those living with blood cancer as part of their cohort. The data suggests some protection against COVID-19.
Public Health England is monitoring the effectiveness of vaccinations in clinical risk groups which will include those with immunosuppression. From the evaluation of the vaccine programme, the data shows that completion of the two dose schedule correlates well with protection from both disease and severe outcomes, including hospitalisation and death.
The Joint Committee on Vaccination and Immunisation (JCVI) has issued interim advice about a potential COVID-19 booster programme from September 2021, starting with those most at risk from serious disease. This will include clinically extremely vulnerable adults and those who are immunosuppressed. The JCVI will continue to review evidence on the use of vaccines in those with immunosuppression and will update its advice as necessary.